PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push

Penny stock PainReform Ltd. (NASDAQ:PRFX) stock climbed on Friday following the company’s recent announcement of a name change to PRF Technologies Ltd.

• PainReform stock is among today’s top performers. Why are PRFX shares rallying?

The stock is trading with a massive volume of 35.49 million versus the average volume of 672.85 thousand, according to Benzinga Pro data.

The name change aims to better represent its broadening portfolio, which now includes specialty pharmaceuticals and AI-driven renewable energy analytics.

The company continues to advance its non-opioid postoperative pain therapy, PRF-110, while also developing new products like OcuRing-K, a dropless ocular therapy for cataract surgery.

Through its majority ownership, LayerBio’s platform supports expansion into additional ophthalmic indications and therapeutic categories.

In the phase 1 study, no treatment-emergent adverse events related to the study drug were observed. No serious adverse events were reported, and no safety issues related to the drug delivery platform were identified. The investigational product and intraocular lens devices remained properly positioned in all treated eyes throughout the study.

Preclinical rabbit studies, similarly, demonstrated favorable local tolerability, with no evidence of ocular tissue abnormalities and no meaningful differences observed between the OcuRing-K and control vehicle.

In addition, PRF Technologies has established a foothold in the renewable energy sector with DeepSolar, an AI-driven analytics platform for solar assets, which is moving into early commercial deployment. This diversification strategy is designed to build long-term value and reduce reliance on any single product outcome.

PRFX Shows Short-Term Strength in Technicals

The stock is currently trading 21.12% above its 20-day simple moving average (SMA) and 12.9% above its 100-day SMA, indicating short-term strength. Over the past 12 months, shares have decreased by 60.93% and are positioned closer to their 52-week lows than highs.

The RSI is at 47.81, which is considered neutral territory, suggesting that the stock is neither overbought nor oversold. Meanwhile, MACD is above its signal line, indicating bullish momentum.

The combination of neutral RSI and bullish MACD suggests mixed momentum.

• Key Resistance: $1
• Key Support: N/A

PRFX Scores High on Benzinga Edge Momentum

Below is the Benzinga Edge scorecard for PainReform, highlighting its strengths and weaknesses compared to the broader market:

• Momentum: Bullish (Score: 83/100) — Stock is outperforming the broader market.
• Quality: N/A — No recent data available.
• Value: Risk (Score: 4/100) — Trading at a steep premium relative to peers.

The Verdict: PainReform stock’s Benzinga Edge signal reveals a classic “High-Flyer” setup. While the Momentum (83) confirms the strong trend, the extremely low Value (4) score warns that the stock is priced for perfection — investors should ride the trend but use tight stop-losses.

PRFX Stock Up

PRFX Price Action: PainReform stock is up 47.72% at $1.22 at the time of publication on Friday, according to Benzinga Pro data.

Photo: Shutterstock